ArticlePain research & management2026
Short- and Midterm Analgesic Outcomes of Ketamine Versus Lidocaine Infusion in Chronic Peripheral Neuropathic Pain: A Retrospective Study.
Article in Pain research & management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06297915 (Evaluation and Comparison of the Effectiveness of Ketamine and Lidocaine Infusion in Peripheral Neuropathic Pain), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation and Comparison of the Effectiveness of Ketamine and Lidocaine Infusion in Peripheral Neuropathic Pain: A Retrospective Study
Who cites it
1 citing paper in PubMed.
- Short- and Midterm Analgesic Outcomes of Ketamine Versus Lidocaine Infusion in Chronic Peripheral Neuropathic Pain: A Retrospective Study.Pain research & management · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntravenous ketamine and lidocaine infusions are increasingly used for chronic peripheral neuropathic pain, particularly in refractory cases. However, comparative data on their short- and midterm analgesic outcomes in routine clinical practice are limited.
methodsThis retrospective study included patients with chronic peripheral neuropathic pain who received intravenous ketamine or lidocaine infusion between January and May 2021. Ketamine was administered at 1 mg/kg/h and lidocaine at 3 mg/kg/h for five consecutive days. Pain intensity and neuropathic pain features were assessed using the Numeric Rating Scale (NRS) and the Douleur Neuropathique 4 (DN4) questionnaire at baseline and at 2 weeks, 2 months, and 6 months after treatment. Clinically meaningful pain relief was defined as a ≥ 50% reduction in pain scores.
resultsA total of 102 patients were analyzed (ketamine group, n = 44; lidocaine group, n = 58). Both groups showed significant reductions in NRS and DN4 scores at all follow-up points compared with baseline (p < 0.01). Clinically meaningful pain relief was more frequent in the ketamine group at 2 weeks (p < 0.01), whereas no significant differences were observed at 2 and 6 months (p > 0.05). Adverse effects occurred more often with ketamine, while lidocaine was associated with fewer side effects (p < 0.05).
conclusionKetamine provided a greater early analgesic response at 2 weeks, whereas both treatments demonstrated comparable midterm efficacy at 2 and 6 months.
trial registrationClinicalTrials.gov identifier: NCT06297915.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.